Stocks · News reference

Helus Pharma shares are trading higher after the company announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026.

Sep 21, 2026, 4:39 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 22, 2026, 9:30 PMBenzinga Newsdesk
Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026
Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"),
HELP
BenzingaSep 21, 2026, 11:38 AMBenzinga Newsdesk
Helus Pharma Presents Four Posters Evaluating HLP003 To Treat Major Depressive Disorder At Psych Congress 2026
Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists
HELP
BenzingaSep 18, 2026, 8:25 AMAvi Kapoor
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.
ABTS AGMH AIFF AMZE BHVN